CCM
JAZZ icon

Camber Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Camber Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,150,000
Closed -$142M – 36
2024
Q4 		$142M Hold
1,150,000
– – 3.28% 8
2024
Q3 		$128M Hold
1,150,000
– – 4.07% 8
2024
Q2 		$123M Hold
1,150,000
– – 3.4% 10
2024
Q1 		$138M Buy
1,150,000
+475,000
+70% +$58.2M 3.39% 10
2023
Q4 		$83M Buy
+675,000
New +$84.2M 2.12% 14

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Camber Capital Management's JAZZ Position: Q1 2025 in Review

Camber Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 1,150,000 shares — an estimated $142M sold.

Camber Capital Management first reported a position in JAZZ in Q4 2023 and held it in 5 quarters. The position peaked at $142M in Q4 2024. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Camber Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Camber Capital Management sold 1,150,000 Jazz Pharmaceuticals shares in Q1 2025, an estimated $142M.
  • Camber Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Camber Capital Management's Jazz Pharmaceuticals position peaked at $142M in Q4 2024.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Camber Capital Management's 13F filing for Q1 2025, filed 15 May 2025.